Revance Therapeutics (RVNC)
(Real Time Quote from BATS)
$3.95 USD
+0.19 (5.05%)
Updated Jul 26, 2024 09:52 AM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 32% (81 out of 250)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.70 | 1.35 | 9.99 |
Current Quarter Estimate | -0.48 | 7.43 | 61.00 |
Year Ago Quarter Estimate | -0.80 | 0.12 | 54.84 |
Next Quarter Estimate | -0.41 | 7.81 | 63.00 |
Next Year Estimate | -0.74 | 37.76 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 52.22 | 15.60 | 15.67 |
Next Year | 59.56 | 10.10 | 9.31 |
Last 5 Years | NA | 1.00 | 8.10 |
Next 5 Years | NA | 20.40 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -2.18 |
Price/Book (MRQ) | NA | 2.09 |
Price/Cash Flow (MRFY) | NA | 16.86 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -134.10% | -54.52% |
Return on Equity (TTM) | NA | -35.38% |
Debt to Equity (MRQ) | NA | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.